Learnings from the Australian First Few X Household Transmission

2 **Project for COVID-19**

1

3

6

- 4 Adrian J Marcato¹, Andrew J Black², James Walker^{2,3}, Dylan Morris², Niamh Meagher^{1,4}, David J Price^{1,4}, Jodie
- 5 McVernon^{1,4,5}, and the Australian FFX Household Transmission Project Group
- 7 Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection
- 8 and Immunity, Melbourne, Australia
- 9 ² School of Mathematical Sciences, The University of Adelaide, Adelaide, Australia
- 10 ³ School of Mathematics & Statistics, The University of Melbourne, Melbourne, Australia
- 12 ⁵ Murdoch Children's Research Institute, Melbourne, Australia

17

21

26

27

28

29

30

31

32

37

38

Research in context 14 15 Evidence before this study 16 The emergence of SARS-CoV-2 was initially characterised by uncertainty over key epidemiological, clinical and virological characteristics of the pathogen. We conducted a prospective household transmission study of 18 confirmed cases of COVID-19 and their household contacts to collect data to understand severity and household 19 transmission dynamics in Australia and add to the emerging evidence base for decision making. Large 20 systematic reviews and meta-analyses of severity and transmission dynamics of SARS-CoV-2 in households have since been published, although estimates vary by setting. 22 23 Added value of this study 24 This is the first multi-jurisdictional prospective household transmission study of its kind for SARS-CoV-2 in 25 Australia. Australia experienced low epidemic activity during the study period in 2020 due to robust public health and social measures including extensive PCR testing of symptomatic persons and isolation of all known contacts of confirmed cases. Hence, we describe the transmission dynamics in our cohort, i.e. in a low incidence setting and provide estimates of the household secondary attack rate, the relative susceptibility of children compared to adults, and transmission from children compared to adults. Implications of all the available evidence Our findings describe the epidemiology of COVID-19 in Australian households in 2020, and demonstrate the 33 effectiveness of public health measures to limit transmission in this setting. Comparisons to other household 34 transmission studies must be interpreted in light of the local epidemiology and context including study design, 35 and sampling methods. Additional research is needed to incorporate genomic and serological data to further 36 study transmission dynamics in our cohort. Continued development of the FFX study platform in Australia will enable integration into surveillance systems and help inform targetted public health responses to future infectious disease emergencies.

39 Abstract 40 41 **Background:** 42 First Few "X" (FFX) studies provide a platform to collect the required epidemiological, clinical and virological 43 data to help address emerging information needs about the COVID-19 pandemic. 44 45 **Methods:** 46 We adapted the WHO FFX protocol for COVID-19 to understand severity and household transmission 47 dynamics in the early stages of the pandemic in Australia. Implementation strategies were developed for 48 participating sites; all household members provided baseline epidemiological data and were followed for 14 49 days from case identification. Household contacts completed symptom diaries and had respiratory swabs taken 50 at baseline, day 7 and day 14, and day 28 where applicable. We modelled the spread of COVID-19 within 51 households using a susceptible-exposed-infectious-recovered-type model, and calculated the household 52 secondary attack rate and key epidemiological parameters. 53 54 **Findings:** 55 96 households with 101 cases and 286 household contacts were recruited into the study between April-October 56 2020. Forty household contacts tested positive for SARS-CoV-2 in the study follow-up period. Our model 57 estimated the household secondary attack rate to be 15% (95% CI 8-25%), which scaled up with increasing 58 household size. Children were less infectious than their adult counterparts but were also more susceptible to 59 infection. 60 61 **Interpretation:** 62 Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from 63 children and adults in Australia, against which properties of variants of concern can be benchmarked. We 64 encountered many challenges with respect to logistics, ethics, governance and data management that may have 65 led to biases in our study. Continued efforts to invest in preparedness research will help to test, refine and 66 further develop Australian FFX study protocols in advance of future outbreaks. 67 68 Funding: 69 Australian Government Department of Health

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Introduction The global spread of the SARS-CoV-2 virus which causes coronavirus disease 2019 (COVID-19) was deemed a pandemic in March 2020. The emergence and global spread of SARS-CoV-2 was initially characterised by uncertainty over key epidemiological, clinical and virological characteristics of the pathogen, particularly, its ability to spread between humans and cause disease in a susceptible population. The First Few "X" (FFX) study protocol for COVID-19 published by the World Health Organization (WHO) provides a platform to collect the required epidemiological, clinical and virological data to help address emerging information needs about the pandemic.²⁻⁴ The FFX study protocol is one of several protocols published by WHO as part of their UNITY study framework, which also includes standardised seroepidemiological study protocols in household, health care and school settings amongst others.^{5,6} In February 2020, the eight Australian state and territory health departments together with the Commonwealth Department of Health and researchers from the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) developed a national plan to implement the WHO FFX study protocol for COVID-19 in Australia. ^{7,8} The Australian FFX Household transmission project aimed to inform understanding of local COVID-19 epidemiology in the early epidemic phases, and provide evidence for the development of guidelines and policy in specifically directing Australia's ongoing public health response. The findings from this investigation are described here. Australia's first epidemic wave in 2020 was driven by returned international travellers and subsequent local transmission in major urban centres across the country. Public health and social measures were introduced to control the escalating epidemic, which included: border closures, expanded case management and contact tracing, and social measures such as density quotients in workplaces and public venues and lockdowns. Mandatory quarantine for returned international travellers was also introduced to reduce the risk of further importation. These measures drove incident cases in Australia to very low levels, and effective elimination (sustained periods of zero case incidence) was achieved in many states and territories by May 2020. A national strategy was set to pursue no community transmission of COVID-19 in the absence of widespread vaccine coverage.9

Breaches from the compulsory quarantine system for returned international travellers led to intermittent periods of local transmission in Australia, particularly in 2020 and the early stages of 2021. Australia's second most populous state, Victoria, experienced a second epidemic wave of activity from late May 2020 to November 2020.

Several Australian states, including New South Wales (Australia's most populous state), Victoria and the Australian Capital Territory now have established community transmission of SARS-CoV-2 due to the delta variant. As of December 13th 2021, there have been 228,930 confirmed cases of COVID-19 in Australia, including 2104 deaths. Of these cases, 220,083 were locally acquired and the majority have been confirmed since June 2021. ^{10,11}

Methods

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Study design, ascertainment and eligibility We adapted the WHO UNITY FFX transmission study protocol for COVID-19, focusing on the household components, with a goal of recruiting 200 households into the project across participating sites.³ Participating sites included New South Wales (NSW; capital Sydney), Victoria (VIC; capital Melbourne), Western Australia (WA; capital Perth), South Australia (SA; capital Adelaide) and Queensland (QLD; capital Brisbane). These adaptations included separating the study into two components: public health (data and viral swab collection as part of enhanced public health unit surveillance activities), and; additional research components (sequencing of positive samples and serology collection and analysis, not presented here), as detailed in Supplementary Table 1. Laboratory confirmed index cases were recruited from the NSW, WA, and QLD state public health units where they were the first case identified in the household according to public health investigations and contact tracing. We recruited co-primary index cases where two household members tested positive within a 24-hour period and there was at least one other household member who was PCR-negative at baseline. In addition, we enriched for index paediatric cases by recruiting from the Royal Children's Hospital Respiratory Infection Clinic (RCH) in VIC. Recruitment was active between April-October 2020, prior to the emergence of any variants of concern (Supplementary Figures 1–4). Households were defined as two or more people living together in a domestic residence or a dwelling or group of dwellings with a shared space. Residential institutions were not included. All locally acquired cases were eligible for recruitment regardless of local source of infection provided they lived within an appropriate geographical area for logistics (i.e., metropolitan areas), and were not in mandated 14-day quarantine. All household members of eligible cases were required to provide their consent to participate. Hospitalised index cases were eligible for recruitment as we assumed that household contacts were exposed by the time hospitalisation of the index case has occurred. Households were excluded when all household members were infected at the time of the initial visit, making the direction of transmission events unclear and unobservable. Epidemiological data were collected from confirmed cases and household contacts as close as possible to laboratory confirmation (day 0/baseline) of the index case, including health status interviews on days 7,14 and where available day 28. The questionnaires collected details on participant demographics, symptoms and

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

vaccine and medical history (details provided in Supplementary Table 2). Household contacts also completed daily symptom diaries (via SMS) and provided specimens in line with Public Health Laboratory Network advice at baseline, days 7,14 and where available day 28. Respiratory swabs were professionally or self-collected depending on study site and were tested by polymerase chain reaction (PCR) in the state of collection.¹² Households were cleared from the project at day 14 if all household contacts were symptom free and tested negative for COVID-19 at previous study timepoints (baseline and days 7/14). Index/primary cases did not complete symptom diaries or provide further swabs during their involvement in the study. Deidentified data were collected and managed using REDCap electronic data capture tools hosted at The University of Melbourne. Ethics approval was not required for the FFX public health components being led through state and territory health departments as the project was recognised as an enhanced national public health surveillance activity. Ethics approval for the FFX project at the RCH site was obtained through the Murdoch Children's Research Institute Ethics Committee (ref: 63666). Analysis Descriptive analyses were performed to explore the characteristics of initially confirmed cases and their household contacts. The household secondary attack rate (HSAR) was defined as the proportion of household contacts that were eventually infected in their study follow-up. We assumed that individuals tested positive for COVID-19 by PCR if and only if they had COVID-19 (i.e., the false positive rate is zero) and infected household contacts had at least one positive PCR test during their follow-up period. We classified all further detected cases within households as secondary cases and assumed that the primary case was the source of infection. We characterised and modelled disease spread within households using an SEIR-type compartmental mathematical model previously developed for pandemic influenza¹³⁻¹⁵, and adapted it for COVID-19 according to early evidence about the incubation period and the generation interval.¹⁶ The model allows for pre- and asymptomatic infection status, and is age-structured allowing for age-specific contact rates.¹⁷ Adults were defined as 18 years old or older, and children were defined as less than 18 years old. The rate of transmission was allowed to scale depending on the household size. Model parameters were estimated using a bespoke Markov chain Monte Carlo method ¹⁵⁻¹⁶; additional model details are outlined in the Supplementary Technical Appendix. Median posterior estimates and 95% credible intervals (CrI) are reported.

Statistical analysis was also conducted to support the choice of variables considered in the mathematical model, identify other variables that may be able to inform the mathematical model, and to align with global FFX and UNITY studies. We used logistic regression models to investigate the association between the HSAR and case-and household-level covariates. Multilevel mixed-effects logistic regression models were used to account for multiple observations per household in the contact-level HSAR analysis. The covariates used in these models are detailed in Supplementary Table 3. Households with co-primary cases were excluded from the statistical HSAR analysis but are included in the household model analysis.

Alpha was set to 0·05, and covariates that had a p-value of <0·2 in univariate regression analysis were included in the multivariable models for the different variable levels. Adjusted odds ratios, adjusted marginal estimates of the HSAR, and associated 95% confidence intervals (95% CIs) were produced for each included covariate.

Data cleaning and descriptive analyses were performed in R, (https://www.r-project.org/). ¹⁸ Statistical HSAR analyses were performed in Stata version 16·0 (StataCorp LLC, College Station, Texas). ¹⁹ All modelling and parameter estimation was performed using Julia 1.6.0 (https://julialang.org). ²⁰

Results

Characteristics of FFX study population

We recruited 96 households with 101 confirmed index cases (due to co-primary cases) and 286 associated household contacts between April 2020 and October 2020. Three households had a false positive index case and were subsequently removed. Four households had incomplete study data. Supplementary Figure 1 shows recruitment into our study over time in relation to the number of locally acquired cases in Australia and in states that contributed data (Supplementary Figures 2–4).

FFX cases had a median age of 29 years (Interquartile range 15–42) and there were slightly more female cases than males. Thirty-five of the confirmed cases were children (<18 years old). Further case and contact participant characteristics can be seen in Table 1. The median household size was 4 (IQR 3–5) and ranged from 2–10 persons (Supplementary Figure 5).

Table 1: Characteristics of included case and household contact participants in the FFX project

	Confirmed cases	Household contacts	
	(n = 101, from 96 households)	(n = 286)	
Age, years	(11 101) 11 011 3 0 11 011 011 011 011 011 011 0	(ii 200)	
Mean (SD)	28.0 (18.3)	28.0 (19.3)	
Median (IQR)	29.0 (15.0–42.0)	26.0 (11.0–44.0)	
Age group, No. (%)		, ,	
<12	21.0 (20.8)	73.0 (25.5)	
12-17	14.0 (13.9)	40.0 (14.0)	
18-49	55.0 (54.5)	122.0 (42.7)	
50+	11.0 (10.9)	51.0 (17.8)	
Sex, No. (%)			
Male	48.0 (47.5)	141.0 (49.5)	
Female	53.0 (52.5)	144.0 (50.5)	
Other	0 (0)	0 (0)	
Received influenza vaccination in previous 12	2 months, No. (%)		
Yes	55.0 (54.5)	131.0 (46.0)	
No	45.0 (44.6)	151.0 (53.0)	
Unknown	1.0 (1.0)	3.0 (1.0)	
Ever had pneumococcal vaccine, No. (%)			
Yes	21.0 (20.8)	82.0 (28.8)	
No	62.0 (61.4)	145.0 (50.9)	
Unknown	18.0 (17.8)	58.0 (20.4)	
Pre-existing health conditions, No. (%)			
Has pre-existing health conditions	27.0 (26.7)	87.0 (30.5)	
Has no pre-existing health conditions	74.0 (73.3)	198.0 (69.5)	
Asthma	8.0 (7.9)	32.0 (11.2)	
Chronic respiratory condition (excluding asthma)	1.0 (1.0)	0 (0)	

Cardiac disease	1.0 (1.0)	4.0 (1.4)
Immunosuppressive condition/therapy	0 (0)	1.0 (0.4)
Diabetes	3.0 (3.0)	8.0 (2.8)
Obese	1.0 (1.0)	5.0 (1.8)
Renal disease	1.0 (1.0)	1.0 (0.4)
Other condition(s)	14.0 (13.9)	41.0 (14.4)

Abbreviations:

IQR = Interquartile range

Household transmission dynamics - mathematical modelling

Of the 286 household contacts recruited into the study, 40 tested positive for SARS-CoV-2 by PCR, with the majority (36/40, 90%) being detected and confirmed by the Day 7 timepoint. The modelling analysis is based on households with sufficient data (92 households comprising of 230 adults and 140 children). Of the included households, 68 had a single case only and experienced no secondary transmission. Final size distributions (i.e., the total number of individuals with laboratory-confirmed infections within a household over the period of monitoring) are shown in Figure 1.




Figure 1: Final size distributions for the 92 households, where N is the size of the household. A final size of 1 indicates no secondary infections. There are no households of size 9 in the dataset.

Posterior distributions for the household secondary attack rate (HSAR) unstratified and stratified by household size, N (HSAR_N), are shown in Figure 3. In both panels of this figure, HSAR is calculated as an average over the households in the dataset to account for the age-structured mixing and difference in adult-child

transmissibility/susceptibility. The HSAR was estimated to be 15% (95%CrI 8–25%, Figure 2a) which increases with household size (Figure 2b).





Figure 2: Posterior distributions for (A) the household secondary attack rate (HSAR) and (B) the household secondary attack rate conditional on household size N (HSAR_N) shown in blue. The grey curve shows the prior distribution. In (B) the dots represent the median of the distributions. HSAR and HSAR_N are calculated as averages over the households in the study and over all ages.

Adults had a higher likelihood of showing symptoms than children (Supplementary Figure 8). Children were found to be more susceptible than adults – the median posterior estimate of the relative susceptibility of children compared to adults was 1·26 (95%CrI 0.75–2.08) as seen in Figure 3A. Children were also less infectious than their adult counterparts – the median posterior estimate of relative transmissibility compared to adults was 0·52 (95%CrI 0.23–1.06), as seen in Figure 3B.



235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

Figure 3: Posterior distributions (blue lines) for the relative susceptibility (A) and transmissibility (B) from children compared to adults, shown in blue. Prior distributions are shown in grey. Household transmission dynamics – statistical analysis Using the contact-level mixed-effects logistic regression model and excluding households with co-primary cases, the HSAR estimate was found to be 12% (95% CI 7–17%). Details of the multivariable logistic regression models at the various factor-levels are presented in Supplementary Table 4. The odds ratio estimate for household size was 1.31 (95% CI 0.97–1.77, p=0.080), representing an average 31% increase in the odds of secondary infection within the household for each one person increase in household size. There is some evidence to suggest that HSAR is associated with the relationship between cases and their contacts parents/guardians/carers and siblings had lower odds of being a secondary case when children were the primary case. The other covariates included in the multivariable models were not found to be associated with the HSAR. Severity Four confirmed cases were hospitalised during their follow-up period (Case hospitalisation rate, 2.8% (4/141), 95% CI 0.9–7.5%) and no deaths were reported in our cohort. Overall, 31.9% (45/141) of confirmed cases were asymptomatic (95%CI 24-40%). 10/101 (9.9%) were asymptomatic primary cases at baseline and 35/40 (87.5%) secondary cases were asymptomatic during their follow-up. Symptoms experienced by household contacts by COVID-19 status can be seen in Supplementary Figure 6.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Discussion

Our household transmission study estimates the HSAR in Australia to be 15% (95%CrI 8–25%) prior to the emergence of variants of concern. We demonstrate that the HSAR increases with household size. Children were relatively more susceptible to infection compared to adults when exposed and were also less infectious than their adult counterparts. The 'gold-standard' mathematical model captures the complex timing and dynamics of transmission in households. Thus, we believe these results to be more robust than those produced by the statistical models. Associations in the statistical modelling need to be taken with caution due to the small sample size and our underlying assumption that all cases we observe in our households are attributed to the primary case – an assumption that is not required in the mathematical model. However, the statistical model results are important as they are broadly consistent with the results from the robust mathematical modelling approach, and represent the standard analytic method that is used to analyse such household transmission studies. They are presented here such that results from our cohort may be fairly compared to other international studies. Our HSAR estimate is consistent with estimates from two systematic review and meta-analyses of household transmission. ^{21,22} We note that our results differ from similar household transmission studies including studies based on the WHO UNITY protocols, such as the FFX study conducted in the UK, which estimated a higher base HSAR that decreased with increasing household size. 23-33 Other studies using population surveillance data, which represent transmission within a broader range of settings than the household, have estimated lower relative susceptibility to SARS-CoV-2 infection for children compared to adults. 34,35 It can be difficult to make direct comparisons between studies that are conducted in different countries and settings due to the unique features of local epidemics and adaptations required for implementation. Studies should be interpreted in light of the local epidemiology and context – considerations should be made for the surveillance and contact tracing capacity, local incidence of COVID-19 cases during study implementation, predominant circulating SARS-CoV-2 variant, the timing and duration of the study, and study design including case ascertainment strategies and specimen sampling methods. Characteristics of individuals affected by COVID-19 and recruited into the study such as socioeconomic status, occupation and size of recruited households may also be significantly different across these studies, and therefore may influence aggregate

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

outcomes. Additionally, differences in public health interventions such as: test, trace and isolate capacity and practices; behavioural and distancing measures; mobility restrictions; communication campaigns; and varying degrees of community engagement and cohesion in response, could also help to explain how estimates may vary across countries and settings. We note ascertainment and recruitment bias in our study cohort that may contribute to some of the differences we observe to other studies - we excluded households where all members of these households were already infected at baseline. This was more likely to exclude smaller households than larger households for participation, and subsequently may have resulted in the HSAR for smaller households being underestimated. Our modelling outputs are therefore influenced more strongly by larger households, particularly three large outbreaks in households with more than five household members. These may be outliers and as such the observed effect could disappear if more data had been collected including from smaller households who experienced rapid transmission making them ineligible for recruitment. Additional sources of data could help us understand the extent to which our results are influenced by our inherent study biases and if our HSAR estimate is an underestimate, or if it is rather a feature of Australia's unique epidemiology, i.e. transmission in a low incidence setting with stringent public health and social measures to reduce within-household and community transmission. We did not observe longer chains of infection in households that had detected secondary transmission. As a result, there were insufficient data to confidently estimate other quantities of interest such as the incubation period, and the pre-symptomatic and symptomatic infectious periods. Although some households experienced larger absolute numbers of cases, in the majority of such households most individuals were already infected at the recruitment baseline or initial swabbing time point (90% of secondary cases were positive by day 7 testing). These outcomes were expected especially as public health units provided extensive advice to reduce the probability of additional spread within the household, including advice on mask use, and how to isolate from each other in their homes. Whilst not the case in this cohort, some cases were removed from their household to further mitigate the risk of spread if their home environment was not suitable for quarantine. We conducted sensitivity analyses to consider how the arbitrary age cut-off of 18 years to define adults and children and the use of our contact matrices were impacting our results. We explored age cut-offs of 8,13 and 16 years of age. We found that the estimated HSAR was not sensitive to changes in the age cut-off (Supplementary

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

Figure 8). There are small differences in the probability of symptom onset for the different age cut-offs (Supplementary Figure 9), although these appear to be centred on the same values. The age cut-off of 16 yielded posterior estimates for the probability of symptom onset that were very similar. There was no sensitivity to the contact matrix being used – this is likely a result of the large number of households who experienced no secondary transmission. Our study has several strengths: This is the first multi-jurisdictional household transmission study of its kind for SARS-CoV-2 in Australia. We provide insights into household transmission with testing of known household contacts regardless of symptoms in a sustained low incidence setting, where there is more certainty about the source of SARS-CoV-2 transmission being from within the household, rather than the community, compared to a higher incidence setting. The pre-existing relationship between public health departments and APPRISE researchers was an enabling factor to provide capacity for the implementation of the study, as Australian health departments were prioritising hospital preparedness and scaling up testing and contact tracing in early 2020 when this study commenced. Our study enriched for paediatric cases through recruitment at the RCH site children were generally not index cases at the other sites, and as such this recruitment strategy provided us with unique insights into household transmission from children in the Australian context. Operationally, our data fields were aligned with the National Notifiable Diseases Surveillance Scheme to harmonise with enhanced surveillance efforts and reduce duplication of data collection where possible. Our bespoke REDCap database provided a central repository to analyse FFX data as a national dataset. Analysis and reporting of FFX data was performed in real time to key national and international stakeholders including, the Communicable Diseases Network Australia (CDNA), WHO Headquarters and the WHO Western Pacific Regional Office. The lack of an Australian specific protocol with a pre-determined implementation strategy led to issues with logistics, and made it difficult to obtain the relevant ethics and governance approvals for all associated research components. We originally anticipated a 6-8 week window of intense recruitment in line with a short and sharp epidemic in early 2020. Strong social and public health control measures including border closures and mandated hotel quarantine reduced case numbers and subsequently the number of eligible cases and households. Two of our sites (QLD and SA) had sustained zero community transmission of COVID-19 by the time they were ready to recruit in April 2020 and WA achieved this in May 2020 after only recruiting four households.

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

We were able to recruit more as epidemic activity increased in VIC and NSW in mid-2020, but case ascertainment in Victoria was limited due to recruitment being limited to the paediatric hospital site. These factors prolonged the duration of our study and may have further contributed to our ascertainment bias. Future research will also involve further collection and analysis of associated genomic and serological data in the FFX research components to better understand and confirm the transmission dynamics in our cohort. Genomic data can help confirm our classification of individuals as we assumed additional cases in the household were attributed to the index case. Serological data may identify historic infections in individuals who continue to present as PCR positive but are non-infectious. Serological data may also be important to identify previously undetected infections in household members especially as the rate of false negatives from PCR may not be insignificant. 36 Together these can provide more accurate data to classify household members and subsequently inform attack rate calculations. Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from children and adults in the Australian context, against which properties of emerging variants of concern such as the Alpha and Delta strains can be benchmarked. ³⁷⁻⁴⁰ We plan to follow our recruited FFX households longitudinally to continue to develop our understanding of household transmission and immunity in the context of emerging variants of concern. This study will be conducted as Australia's vaccination program continues and throughout the eventual establishment of community transmission of SARS-CoV-2 in Australia. Research is also currently underway to formally evaluate the implementation of our FFX study to help consolidate on lessons learnt and inform preparedness efforts for future FFX studies in Australia for COVID-19 or other infectious disease emergencies. Conclusion The Australian FFX project for COVID-19 has been useful to provide valuable insight into the epidemiology of SARS-CoV-2 in Australia despite encountering many challenges in the planning and implementation phases with respect to logistics, ethics, governance and data management. Continued efforts to invest in preparedness research will help to test, refine and further develop Australian FFX study protocols in advance of future outbreaks of concern and ensure they are embedded in pandemic response plans. 41,42 Being able to rapidly activate and provide high-quality information in real-time will be useful for epidemic situational assessment and

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

modelling studies in response to future outbreaks of concern, to ensure a more proportionate, equitable and targeted public health response and help reduce disease impact. **Funding Sources:** The public health components of the Australian FFX Household Transmission Project were funded by the Australian Government Department of Health. **Acknowledgements:** The Australian FFX Household Transmission Project Group (alphabetical order): Ross Andrews, Laura Bannerman, Christina Bareja, Andrew Black, Douglas Boyle, Georgina Collins, Jo Collins, Loral Courtney, Nigel Crawford, Katina D'Onise, Lucy Deng, Kate Dohle, Andrew Dunn, Paul Effler, James Fielding, Erin Flynn, Rob Hall, Sonia Harmen, Troy Laidlow, Eileen Lam, Adrian Marcato, Jodie McVernon, Niamh Meagher, Adriana Milazzo, Caroline Miller, Dylan Morris, Janette Mulvey, Sera Ngeh, Genevieve O'Neill, Kate Pennington, Priyanka Pillai, Ben Polkinghorne, David Price, Victoria Pye, Joshua Ross, Freya Shearer, Miranda Smith, Paula Spokes, Andrew Steer, Mark Taylor, Shidan Tosif, Florian Vogt, James Walker, Nicholas Wood. The Communicable Diseases Network Australia, for their input in the planning stages of the project, oversight and review of the article.

403 **References:** 404 World Health Organization. WHO Director-General's opening remarks at the media briefing on 405 COVID-19 - 11 March 2020 [Internet]; 2020 (https://www.who.int/director-406 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020, accessed 6th December 2021) 407 408 409 World Health Organization, Global Research on coronavirus disease (COVID-19); 2021 410 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-411 coronavirus-2019-ncov, accessed 6th December 2021) 412 413 World Health Organization, The first few X cases and contacts (FFX) investigation protocol for 414 coronavirus disease 2019 (COVID-19), version 2.2; 2021 (https://www.who.int/publications/i/item/the-415 first-few-x-cases-and-contacts-(-ffx)-investigation-protocol-for-coronavirus-disease-2019-(-covid-19)-416 version-2.2, accessed 6th December 2021) 417 418 Marcato AJ, Fielding J, Crooks K et al. The ongoing value of First Few X studies for COVID-19 in the 419 Western Pacific Region. In press article. 420 421 World Health Organization, Coronavirus disease (COVID-19) technical guidance: The Unity Studies: 422 Early Investigation Protocols; 2021 (https://www.who.int/emergencies/diseases/novel-coronavirus-423 2019/technical-guidance/early-investigations, accessed 6th December 2021) 424 425 Bergeri I, Lewis HC, Subissi L et al. Early epidemiological investigations: World Health Organization 426 UNITY protocols provide a standardized and timely international investigation framework during the 427 COVID-19 pandemic. Influenza Other Respir Viruses. 2021 [Epub ahead of print]. 428 doi:10.1111/irv.12915 pmid:34611986 429 430 The Australian Partnership for Preparedness Research on Infectious Disease emergencies, 2021 (431 https://www.apprise.org.au/, accessed 6th December 2021) 432

433 The Australian Partnership for Preparedness Research on Infectious Disease emergencies. First Few X' 434 (FFX) research project to enhance the public health response to COVID-19 in Australia. 2021, 435 (https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-436 response-to-covid-19-in-australia/, accessed 6th December 2021) 437 438 Australian Government Department of Health, Australian Health Protection Principal Committee 439 (AHPPC) statement on strategic direction, 2020; (https://www.health.gov.au/news/australian-health-440 protection-principal-committee-ahppc-statement-on-strategic-direction, accessed 6th December 2021) 441 442 10 Australian Government Department of Health, Coronavirus (COVID-19) current situation and case 443 numbers, 2021; https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-444 alert/coronavirus-covid-19-current-situation-and-case-numbers, accessed 6th December 2021) 445 446 11 COVID-19 National Incident Room Surveillance Team (2021). COVID-19 Australia: Epidemiology 447 Report 55 Reporting period ending 21 November 2021. Communicable diseases intelligence 448 (2018), 45, 10.33321/cdi.2021.45.65. https://doi.org/10.33321/cdi.2021.45.65 449 450 12 Australian Government Department of Health, Public Health Laboratory Network Publications, 2021 451 (https://www1.health.gov.au/internet/main/publishing.nsf/Content/Publications-13, accessed 6th 452 December 2021) 453 454 13 Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and 455 transmissibility from data collected during first few hundred studies. Epidemics. 2017;19:61-73. 456 457 14 Black, AJ. Importance sampling for partially observed temporal epidemic models. Statistics and 458 Computing, 2019, 29, 617-630 459 460 15 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models. 461 Math Biosci. 2019;317:108266. 462

463 16 Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) 464 From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 465 2020;172(9):577-82. 466 467 17 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and 468 demographic data. PLOS Computational Biology. 2017;13(9):e1005697. 469 470 18 R Core Team (2021). R: A language and environment for statistical computing. R Foundation for 471 Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ 472 473 19 StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. 474 475 20 Julia: A Fresh Approach to Numerical Computing. Jeff Bezanson, Alan Edelman, Stefan Karpinski, 476 Viral B. Shah. (2017) SIAM Review, 59: 65–98. doi: 10.1137/141000671.pdf. 477 478 21 Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of SARS-479 CoV-2: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(12):e2031756-e. 480 481 22 Thompson HA, Mousa A, Dighe A et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-482 CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. Clinical 483 Infectious Diseases. 2021;73(3):e754-e64. 484 485 23 House T, Pellis L, Pouwels KB et al., Inferring Risks of Coronavirus Transmission from Community 486 Household Data. Preprint. arXiv. 2021; https://arxiv.org/abs/2104.04605 487 488 24 Dattner I, Goldberg Y, Katriel G et al. The role of children in the spread of COVID-19: Using 489 household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. 490 PLOS Computational Biology. 2021;17(2):e1008559. 491

492 25 Li F, Li Y-Y, Liu M-J et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility 493 and infectivity in Wuhan: a retrospective observational study. The Lancet Infectious Diseases. 494 2021;21(5):617-28. 495 496 26 Pung R, Park M, Cook AR, Lee VJ. Age-related risk of household transmission of COVID-19 in 497 Singapore. Influenza Other Respir Viruses. 2021;15(2):206-8. 498 499 27 Reukers DFM, van Boven M, Meijer A, et al. High infection secondary attack rates of SARS-CoV-2 in 500 Dutch households revealed by dense sampling. Clinical Infectious Diseases. 2021. 501 502 28 Cerami C, Popkin-Hall ZR, Rapp T et al. Household transmission of SARS-CoV-2 in the United 503 States: living density, viral load, and disproportionate impact on communities of color. Clin Infect Dis. 504 2021. 505 506 29 Lewis NM, Chu VT, Ye D et al. Household Transmission of SARS-CoV-2 in the United States. Clin 507 Infect Dis. 2020. 508 509 30 Ng OT, Marimuthu K, Koh V et al. SARS-CoV-2 seroprevalence and transmission risk factors among 510 high-risk close contacts: a retrospective cohort study. The Lancet Infectious Diseases. 2021;21(3):333-511 43. 512 513 31 Ratovoson R, Razafimahatratra R, Randriamanantsoa L et al. Household transmission of COVID-19 514 among the earliest cases in Antananarivo, Madagascar. Influenza Other Respir Viruses. 2021. 515 516 32 Bernal JL, Panagiotopoulos N, Byers C et al. Transmission dynamics of COVID-19 in household and 517 community settings in the United Kingdom. medRxiv. 2020:2020.08.19.20177188. 518 519 33 Miller E, Waight PA, Andrews NJ et al. Transmission of SARS-CoV-2 in the household setting: A 520 prospective cohort study in children and adults in England. J Infect. 2021. 521

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

34 Viner RM, Mytton OT, Bonell C et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatrics. 2021;175(2):143-56. 35 Davies NG, Klepac P, Liu Y et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature Medicine. 2020;26(8):1205-11. 36 Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020;173(4):262-7. 37 Davies NG, Abbott S, Barnard RC et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055. 38 Wibmer CK, Ayres F, Hermanus T et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021:2021.01.18.427166. 39 Naveca F, Nascimento V, Souza V et al. COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1, 25 February 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-275494/v1 40 Public Health England, SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 11; 2021 (https://www.gov.uk/government/publications/investigation-of-novel-sarscov-2-variant-variant-of-concern-20201201, accessed 6th December 2021) 41 Australian Health Sector Emergency Response Plan for Novel Coronavirus (COVID-19); 2020 (https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-planfor-novel-coronavirus-covid-19, accessed 6th December 2021)

42 Australian Government Department of Health. Australian Health Management Plan for Pandemic Influenza; 2014 (https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-ahmppi.htm_, accessed 6th December 2021)

Supplementary Appendix

	Summary	Funding source	
Public health component	 Data collection from confirmed cases as close as possible to laboratory confirmation including status interviews on days 7,14 ± 28 Data collection from household contacts including daily symptom diaries and status interviews on days 7,14, ± 28 Specimens at days 0,7,14 ± 28 from household contacts. Professionally collected or self-collected depending on site, in line with the Australian Public Health Laboratory Network advice Households to end participation where the entire household is symptom and COVID-19 free at the day 14 time point 	Australian Commonwealth Department of Health	
Research component 1 – components of protocol not deemed to be essential public health activity in February 2020	 Sequencing of previously collected positive specimens in the public health project Collection of blood sample from household contacts after any self-isolation/quarantine periods have been served 	APPRISE Centre of Research Excellence	
Research component 2 – extended follow-up of FFX cohort over 3 year period	 Repeat serology from current recruits Ongoing FFX recruitment – trialling FluTracking arm and Aboriginal Community Controlled Health Organisation led First Nations pilot study 	Australian National Health and Medical Research Council (partnership grant in collaboration with the Australia Commonwealth Department of Health and Hunter New Englan Local Health District)	

Supplementary Table 2: Data collected in the Australian FFX questionnaires

Case data	Contact data		
- Demographic data; age, sex, pregnancy	- Demographic data; age, sex, pregnancy		
 Aboriginal and Torres Strait Islander status 	 Aboriginal and Torres Strait Islander status 		
- Household demographics; household size and number	 Relationship to case, and extent of contact 		
of bedrooms, postcode	- Symptom data (including symptom diaries)		
- Symptom data (including symptom diaries where	- Comorbidity data		
relevant)	- Laboratory data (swabs)		
- Comorbidity data	- Influenza/pneumococcal vaccination data		
- Laboratory data (swabs)	- Follow up data; including hospitalisation status at study		
- Influenza/pneumococcal vaccination data	time points		
- Follow up data; including hospitalisation status at study	-		
time points			
560			

Supplementary Table 3: Covariates explored in the univariate and multivariable logistic and negative binomial

regression models

562

563

564

565

566

567

568

570

Case covariates

- Number of respiratory symptoms experienced by the case (fever, cough, sore throat, shortness of breath, loss of taste, loss of smell, runny nose)
- Does the case have conditions that may affect ability to transmit onwards or not (asthma, chronic respiratory disease, immunosuppression)
- Time between date of symptom onset and date of baseline test as a proxy for time before PHU intervention
- Gender of primary case
- Hospitalisation of the case

Household covariates

- Household size (for direct comparison to the mathematical model)
- Household density proxy calculated as HH size divided by the number of bedrooms in the household
- Composition of household family (parent/s and children), share-house, complex (multigenerational family or other)
- Number of children (<18 years) in household

Contact covariates

- Gender of contacts
- Relationship to case
- Number of measured contact events at baseline (include sharing of spaces, facilities, bedroom)
- Time between the case baseline test and first contact test as a proxy for time before PHU intervention
- Number of pre-existing conditions (asthma, chronic respiratory condition, cardiac disease, immunosuppressive condition/therapy, diabetes, obesity, liver disease, renal disease, neurological disorder)

Supplementary Table 4: Results from the multivariable logistic regression models of HSAR. Covariates were included in the multivariable logistic regression models if they had a p-value of <0.2 in univariate regression

analysis. The estimates presented here are exclusive of households with co-primary cases.

Covariate	Variable level	Adjusted odds	p-value	Adjusted HSAR estimate
		ratio (95% CI)		(95% CI)
Household-level mod	del (n=91)			
Household size#	2	Overall – 1·35	0.054*	0.11 (0.02, 0.21)*
	3	(0.99, 1.84)*		0.15 (0.07, 0.24)*
	4			0.20 (0.11, 0.28)*
	5			0.26 (0.15, 0.35)*
	6			0.33 (0.16, 0.46)*
	7			0.41 (0.16, 0.60)*
	8			0.49 (0.15, 0.75)*
	9			0.57 (0.15, 0.90)*
	10			0.65 (0.24, 0.96)*

Case-level model $(n=91)$				
Ever hospitalised (from	No	Ref		0.21 (0.13, 0.30)
case-level model)	Yes	2.56 (0.29, 22.34)	0.395	0.40 (0, 0.90)
Number of transmitting	0	Ref		0.20 (0.11, 0.29)
conditions (asthma,	1	2.75(0.61, 12.34)	0.186	0.40 (0.07, 0.74)
chronic respiratory				
disease,				
immunosuppression)				
Contact-level model (n=2	276)			
Multilevel mix effects log		incorporating cluster	ing by household	d
Contact relationship to	Child	Ref	-	0.22 (0.10, 0.33)
case				
	Other***	0.60(0.01, 4.14)	0.271	0.08(0, 0.23)
	Parent/guardian/carer	0.07 (0.01, 0.39)	< 0.01	0.04 (0, 0.09)
	Partner/spouse	0.57 (0.15, 2.24)	0.422	0.16 (0.06, 0.27)
	Sibling	0.23 (0.04, 1.16)	0.074	0.1 (0.01, 0.17)
Sex	Female	Ref		0.10 (0.04, 0.14)
Sex	Male	2.37 (0.80, 6.95)	0.117	0.14 (0.08, 0.20)
Number of pre-existing	0	Ref	-	0.10 (0.05, 0.14)
conditions (as defined	1	6.37 (1.40, 28.89)	0.016	0.26 (0.10, 0.39)
in Supplementary Table 3)	2	2.47 (0.10, 62.85)	0.585	0.16 (0, 0.42)

^{*} Results from the univariate regression models are presented where only one covariate was eligible to be

572

573

574

575

576


577

included in the multivariable model


^{***} Includes grandparents, grandchildren, partners of household contacts, housemates

[#]HH sizes were fit as a continuous variable and estimates presented for the range of household sizes in our study


population. We didn't have a household of size 9, and so we are extrapolating from the data that we have




Supplementary Figure 1: Recruitment into the Australian FFX project (bars) and confirmed cases across Australia (line). Note that the epidemic curve represents includes all cases reported in Australia from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the project.




Supplementary Figure 2: Recruitment into the Australian FFX project (bars) and confirmed cases in New South Wales (line). Note that the epidemic curve represents includes all cases reported in New South Wales from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the project.



Supplementary Figure 3: Recruitment into the Australian FFX project (bars) and confirmed cases in Victoria (line). Note that the epidemic curve represents includes all cases reported in Victoria from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the project identified at the Royal Children's Hospital.




Supplementary Figure 4: Recruitment into the Australian FFX project (bars) and confirmed cases at the Western Australia (line). Note that the epidemic curve represents includes all cases reported in Western Australia from the commencement of the project (April 6th 2020), and not necessarily all eligible local cases for inclusion into the project.




Supplementary Figure 5: Histogram of recruited household sizes by state.

632


633




Supplementary Figure 6: Symptoms reported by household contacts during study follow-up.



Supplementary Figure 7: Prior distribution on the generation time implied by the prior distributions on the basic parameters discussed in the Supplementary Technical Appendix. The solid line represents the mean and the shaded region the 95% Credible Intervals.



Supplementary Figure 8: Posterior distributions for the household secondary attack rate using different age cut-offs to define children and adults (in years).



Supplementary Figure 9: Posterior distributions for the probability of displaying symptoms, conditional on testing positive for adults (blue) and children (green) defined at various age cut-offs (in years). The grey curve indicates the prior distribution.

Additional model details - modelling appendix


Disease spread within a household was characterised using an SEIR-type compartmental mathematical model previously developed for pandemic influenza¹⁻³, adapted to COVID-19. The model allows for pre- and asymptomatic infection status, and is age-structured with age-specific contact rates.⁴ Adults were defined as 18 years old or older, and children were defined as less than 18 years old.

The structure of the model is illustrated in Appendix Figure 1 with associated parameters described in Appendix Table 1. The classes are split into multiple, identical stages, which makes the distribution of time spent within each class Erlang distributed (rather than exponential) to more accurately reflect the distribution time in each period. The number of stages was chosen to reflect evidence about the distributions of the incubation period and/or the generation interval.⁵

The rate of transmission scales depending on the household size, *N*, and the ages of individuals that they make contact within a household. The transmission rate from an infectious adult of age n to a susceptible adult of age m is given by

$$\frac{\beta c_{n,m}}{(N-1)^{\alpha}}$$

where parameters are as described in Appendix Table 1. The infection rate is scaled based on an individual's age – specifically, the rate of transmission from an adult to a child is multiplied by r_s , the rate of transmission from a child to an adult is multiplied by r_t , and the rate of transmission from a child to another child is multiplied by r_t . The terms r_s and r_t represent the relative susceptibility and transmissibility of children, respectively.



Appendix Figure 1: SEIR model structure for the spread of COVID-19 within a household. This illustrates the epidemiological states an individual may be in and how they transition between these states. These states are: S (susceptible); $E_{1,2,3}$ (exposed); $P_{1,2,3}$ (pre-symptomatic and infectious); $I_{1,2}$ (infectious and symptomatic); $I_{1a,2a}$ (infectious and asymptomatic), and; R (recovered). The red arrow indicates the transition when an individual begins to show symptoms. At some point within the infectious period an individual may be hospitalised, and hence removed from the household.

Appendix Table 1: Parameters for the model shown in Appendix Figure 1.

Parameter	Description
N	Size of household
$c_{n,m}$	Contact rate between age n and m individuals
$1/\sigma$	Average time spent in exposed states
1/λ	Average time spent in pre-symptomatic states
$1/\gamma$	Average time spent in states I_1 , I_2 , I_{1a} and I_{2a}
p_a	Probability of developing symptoms for adults
p_c	Probability of developing symptoms for children
β	Rate of infection from adults to adults per contact in a

	household of size 2
$r_{\scriptscriptstyle S}$	Relative susceptibility of children
r_t	Relative transmission from children
α	Household size transmission scaling term

Bayesian inference is performed targeting the parameters of the model using a custom Markov chain Monte Carlo method. The likelihood is estimated using a particle filter that targets the final size of the outbreak within a house, thus we ignore temporal information such as the timing of tests and symptom onset. This approach is adopted as there is very little temporal information and what is available is poorly resolved.

Prior distributions for all parameters of the model are given below:

$$R_{0} = \beta(\lambda^{-1} + \gamma^{-1}) \sim \text{Gamma}(5, 1/3)$$

$$\sigma^{-1} \sim \text{N}(5 \cdot 56 - \lambda^{-1}, 0 \cdot 41^{2})$$

$$\lambda^{-1} \sim \text{U}(0, 2)$$

$$\gamma^{-1} - 1 \sim \text{Gamma}(5, 3/5)$$

$$r_{s} \sim \text{Gamma}(5, 1/7)$$

$$r_{t} \sim \text{Gamma}(10, 1/9)$$

$$p_{a} \sim \text{Beta}(4, 8/3)$$

$$p_{c} \sim \text{Beta}(4, 8/3)$$

$$\alpha \sim \text{N}(1/2, 1/4), \text{truncated to } (-1.5, 1.5)$$

The model priors for the average latent period and pre-symptomatic infectious periods (σ^{-1} and λ^{-1}) were fitted using data on exposure windows and symptom onset times from Lauer et al. (2020).⁵ This distribution is calculated using a particle marginal Metropolis Hastings method assuming a uniform [0,10] prior on $1/\sigma$ (the average exposed period), a uniform [0,10] prior on $1/\lambda$ (the average pre-symptomatic infectious period) and discrete uniform (1,15) shape parameters for each distribution. The resulting joint distribution on σ^{-1} and λ^{-1} was found to be well approximated by the parametric combination given above.

The prior for the average infectious period γ^{-1} was chosen with a mode of 3.4 days and a mean of 4 days. The key quantity which arises from these temporal parameters is the generation time. The distribution for this was obtained by sampling from the joint prior of the parameters $(R_0, \sigma^{-1}, \lambda^{-1}, \gamma^{-1})$ and using simulation of the full compartmental model in a fully susceptible population. The final size depends on the transmissibility and generation time distribution, and the effective prior for the generation time distribution is shown in Supplementary Figure 7.6 This is consistent with the distribution reported in *Ferretti et. al* (2020).

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733 734

735

736 737

738

739

740 741

742

743

744

745

Prior distributions were set on the relative susceptibility, r_s and transmissibility, r_t such that the prior distribution for r_s had mode 0.5 and the prior distribution for r_t has mode 1. Each of these distributions are relatively uninformative which captures the prior uncertainty in the parameter values surrounding the differences between children and adults in relation to transmission. The prior distribution on both the observation probabilities was centered around 0.6. The prior distribution on the effect of household size, α was taken to be a Normal distribution with mean 0.5 and variance 0.25 truncated on the interval (-1.5, 1.5). This facilitates the possibility of density dependent transmission when $\alpha = 0$ and frequency dependent transmission when $\alpha = 1$. References for supplementary information Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and transmissibility from data collected during first few hundred studies. Epidemics. 2017;19:61-73. Black, AJ. Importance sampling for partially observed temporal epidemic models. Statistics and Computing, 2019, 29, 617-630 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models. Math Biosci. 2019;317:108266. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLOS Computational Biology. 2017;13(9):e1005697. Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82. Ball F. A Unified Approach to the Distribution of Total Size and Total Area under the Trajectory of Infectives in Epidemic Models. Advances in Applied Probability. 1986;18(2):289-310 Ferretti L, Wymant C, Kendall M et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020;368(6491):eabb6936.